Stockscreener 앱 받기
9.27
3.13%
-0.30
시간 외 거래:
9.31
0.04
+0.43%
전일 마감가:
$9.57
열려 있는:
$9.6
하루 거래량:
1.49M
Relative Volume:
0.79
시가총액:
$784.63M
수익:
-
순이익/손실:
$-43.16M
주가수익비율:
-16.85
EPS:
-0.55
순현금흐름:
$-29.31M
1주 성능:
-11.63%
1개월 성능:
-13.69%
6개월 성능:
+36.42%
1년 성능:
+55.28%
1일 변동 폭
$9.07
$9.675
1주일 범위
$9.07
$10.22
52주 변동 폭
$3.25
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
AVXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.27 | 784.63M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Receives "Buy" Rating from D. Boral Capital - MarketBeat
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’ - Yahoo Finance
Anavex Life Sciences Secures New Patent For ANAVEX®2-73 - Evrim Ağacı
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio - The Manila Times
Anavex Secures Crucial Patent for Alzheimer's Drug Delivery Breakthrough - StockTitan
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why - Nasdaq
Long-Term investors in shares of Anavex Life Sciences Corp. - openPR
Best Momentum Stocks to Buy for January 21st - Yahoo Finance
New Strong Buy Stocks for January 21st - Yahoo Finance
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 9.4%What's Next? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 6.3%Time to Sell? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 9.4%Here's Why - MarketBeat
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease - The Manila Times
Anavex's Oral Alzheimer's Drug Shows Breakthrough 36% Disease Slowdown in Phase 3 Trial - StockTitan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Holdings Raised by Barclays PLC - MarketBeat
Barclays PLC Acquires 64,101 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Dru - Asianet Newsable
Anavex Life Sciences: Pioneering Precision Medicine for CNS Disorders - Big News Network
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from D. Boral Capital - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) vs. Pluri (NASDAQ:PLUR) Critical Comparison - Defense World
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease - Seeking Alpha
Commit To Buy Anavex Life Sciences Corp At $7, Earn 28.6% Using Options - Nasdaq
Jane Street Group LLC Sells 119,531 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Jane Street Group LLC Trims Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 11.3%What's Next? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Trading 6.3% HigherStill a Buy? - MarketBeat
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Anavex Life Sciences to Present at JP Morgan Healthcare Conference 2025: Focus on Neurological Breakthroughs - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap UpShould You Buy? - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Short Interest Up 5.7% in December - Defense World
Franklin Resources Inc. Boosts Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Expands By 5.7% - MarketBeat
Geode Capital Management LLC Increases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Geode Capital Management LLC Increases Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? - Yahoo Finance
Barclays PLC Boosts Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Barclays PLC - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 7.6%What's Next? - MarketBeat
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy - Yahoo Finance
HC Wainwright Issues Positive Estimate for AVXL Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of AVXL Q1 Earnings - Defense World
Anavex Life Sciences: Short-Squeeze Target Gains Traction - Investing.com
Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Price Target Raised to $42.00 at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) vs. Autolus Therapeutics (NASDAQ:AUTL) Head-To-Head Analysis - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 6.9% After Analyst Upgrade - Defense World
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):